top of page

Pain Research (Archived)

Research Topic

Cannabinoids are analgesic in man, but their use is limited by their psychoactive properties. One way to avoid cannabinoid receptor subtype 1 (CB1R)-mediated central side-effects is to develop CB1R agonists with limited CNS penetration. Activation or peripheral CB1Rs has been proposed to be analgesic, but the relative contribution of peripheral CB1Rs to the analgesic effects of systemic cannabinoids remains unclear. Here we addressed this by exploring the analgesic properties and site of action AZ11713908, a peripherally restricted CB1R agonist, in rodent pain models.

A Peripherally Restricted Cannabinoid Receptor Agonist Produces Robust Anti-Nociceptive Effects In Rodent Models Of Inflammatory And Neuropathic Pain

SARS-CoV-2 is a new beta coronavirus first reported in China with a 14-day incubation period [1]. Infected persons may be either asymptomatic carriers, during which time they can transmit the virus to others [2], or develop mild disease involving cough and rhinitis, with or without mild pneumonia.

Acute Inflammation And Pathogenesis Of SARS-CoV-2 Infection: Cannabidiol As A Potential Anti-Inflammatory Treatment?

Chronic pain affects a significant proportion of the population and presents a major challenge to clinicians and pain specialists. Despite the availability of pharmacologic treatment options such as opioids, many patients continue to experience persistent pain. Cannabinoids present an alternative option with some data on efficacy; however, to date, a systematic review of adverse events (AEs) assessment and reporting in randomized clinical trials (RCTs) involving cannabinoids has not been performed.

Adherence To Consolidated Standards Of Reporting Trials Guidelines For Reporting Safety Outcomes In Trials Of Cannabinoids For Chronic Pain

Neuropathic pain is a neurological disorder that strongly affects the quality of life of patients. The molecular and cellular mechanisms at the basis of the neuropathic pain establishment still need to be clarified. Among the neuromodulators that play a role in the pathological pain pathways, endocannabinoids could be deeply involved in both neuronal and non-neuronal mechanisms responsible for the appearance of tactile allodynia.

Allodynia Lowering Induced By Cannabinoids And Endocannabinoids (ALICE)

Combining drugs not only reduces specific adverse effects of each of the drug at a higher dose but also may lead to enhanced efficacy. Taking into the consideration, the pharmacological similarities between opioids and cannabinoids, we assumed that combination of cannabinoids with noradrenaline re-uptake inhibitors might also be effective.

Analysis Of The Anti-Allodynic Effects Of Combination Of A Synthetic Cannabinoid And A Selective Noradrenaline Re-Uptake Inhibitor In Nerve Injury-Induced Neuropathic Mice

Cannabidiol (CBD) is a phytocannabinoid with multiple pharmacological effects and several potential therapeutic properties. Its low oral bioavailability, however, can limit its clinical use. Preliminary results indicate that fluorination of the CBD molecule increases its pharmacological potency.

Antinociceptive Effects Of HUF-101, A Fluorinated Cannabidiol Derivative

Osteoarthritis (OA) is a multifactorial joint disease, which includes joint degeneration, intermittent inflammation, and peripheral neuropathy. Cannabidiol (CBD) is a noneuphoria producing constituent of cannabis that has the potential to relieve pain. The aim of this study was to determine whether CBD is anti-nociceptive in OA, and whether inhibition of inflammation by CBD could prevent the development of OA pain and joint neuropathy.

Attenuation Of Early Phase Inflammation By Cannabidiol Prevents Pain And Nerve Damage In Rat Osteoarthritis

Cannabinoid receptors include CB1, which is predominantly expressed in the brain, and CB2, which is primarily found in the cells of the immune system. Manipulation of endocannabinoids and/or use of exogenous cannabinoids in vivo can constitute a potent treatment modality against inflammatory disorders.

Cannabinoids As Novel Anti-Inflammatory Drugs

This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment.

Cannabinoids In The Management Of Difficult To Treat Pain

Inflammation and oxidative stress play main roles in neurodegeneration. Interestingly, different natural compounds may be able to exert neuroprotective actions against inflammation and oxidative stress, protecting from neuronal loss. Among these natural sources, Cannabis Sativa represents a reservoir of compounds exerting beneficial properties, including cannabigerol (CBG), whose antioxidant properties have already been demonstrated in macrophages.

In Vitro Model Of Neuroinflammation: Efficacy Of Cannabigerol, A Non-Psychoactive Cannabinoid

Clinical trials investigating the use of cannabinoid drugs for the treatment of intestinal inflammation are anticipated secondary to preclinical literature demonstrating efficacy in reducing inflammation.

The Use Of Cannabinoids In Colitis: A Systematic Review And Meta-Analysis

Current arthritis treatments often have side-effects attributable to active compounds as well as route of administration. Cannabidiol (CBD) attenuates inflammation and pain without side-effects, but CBD is hydrophobic and has poor oral bioavailability. Topical drug application avoids gastrointestinal administration, first pass metabolism, providing more constant plasma levels.

Transdermal Cannabidiol Reduces Inflammation And Pain-Related Behaviors In A Rat Model Of Arthritis

bottom of page